AKOUOS INC (AKUS) Stock Price, Quote, News and Overview
NASDAQ:AKUS - Nasdaq - US00973J1016 - Common Stock - Currency: USD
AKUS Quote, Performance and Key Statistics
13.29
+0.14 (+1.06%)
The current stock price of AKUS is 13.29 USD. In the past month the price increased by 1.22%. In the past year, price increased by 70.17%.
AKUS Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About AKUS
Company Profile
Akouos, Inc. is a precision genetic medicine company, which engages in the development of precision genetic medicines to restore and preserve hearing in genetically-defined patient populations. The company is headquartered in Boston, Massachusetts and currently employs 103 full-time employees. The company went IPO on 2020-06-26. The firm is focused on developing precision therapies for forms of sensorineural hearing loss. The firm's genetic medicine platform that incorporates a proprietary vector library consisting of variants of a small virus commonly used in gene therapy, known as adeno-associated virus (AAV), and a novel delivery approach. The firm is focused on executing its initiatives, which include the advancement of its lead product candidate, AK-OTOF, is a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene; expansion of its pipeline to include programs focused on other monogenic conditions as well as inner ear conditions of complex etiology, such as AK-antiVEGF for vestibular schwannoma; and development of internal manufacturing capabilities, and a commercial infrastructure.
Company Info
AKOUOS INC
645 Summer Street, Suite 200
Boston MASSACHUSETTS 02210 US
CEO: Emmanuel Simons
Employees: 103
Company Website: https://akouos.com/
Phone: 18574101818.0
AKOUOS INC / AKUS FAQ
What is the stock price of AKOUOS INC today?
The current stock price of AKUS is 13.29 USD. The price increased by 1.06% in the last trading session.
What is the ticker symbol for AKOUOS INC stock?
The exchange symbol of AKOUOS INC is AKUS and it is listed on the Nasdaq exchange.
On which exchange is AKUS stock listed?
AKUS stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for AKOUOS INC stock?
11 analysts have analysed AKUS and the average price target is 17.68 USD. This implies a price increase of 33.03% is expected in the next year compared to the current price of 13.29. Check the AKOUOS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is AKOUOS INC worth?
AKOUOS INC (AKUS) has a market capitalization of 491.01M USD. This makes AKUS a Small Cap stock.
How many employees does AKOUOS INC have?
AKOUOS INC (AKUS) currently has 103 employees.
What are the support and resistance levels for AKOUOS INC (AKUS) stock?
AKOUOS INC (AKUS) has a support level at 13.27 and a resistance level at 13.32. Check the full technical report for a detailed analysis of AKUS support and resistance levels.
Should I buy AKOUOS INC (AKUS) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of AKUS, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of AKUS, evaluating the profitability, health, valuation and growth aspects
- AKOUOS INC (AKUS) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- AKOUOS INC (AKUS) Sales and EPS estimates to see what analysts future expectations are.
- AKOUOS INC (AKUS) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- AKOUOS INC (AKUS) Insider and Institutional Ownership to learn about the owners and their transactions.
- AKOUOS INC (AKUS) Stock Chart to make your own analysis
- AKOUOS INC (AKUS) Latest news and press-releases to stay up to date.
Does AKOUOS INC (AKUS) stock pay dividends?
AKUS does not pay a dividend.
When does AKOUOS INC (AKUS) report earnings?
AKOUOS INC (AKUS) will report earnings on 2023-03-27.
What is the Price/Earnings (PE) ratio of AKOUOS INC (AKUS)?
AKOUOS INC (AKUS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.62).
AKUS Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to AKUS. When comparing the yearly performance of all stocks, AKUS is one of the better performing stocks in the market, outperforming 99.76% of all stocks.
AKUS Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to AKUS. AKUS has a great financial health rating, but its profitability evaluates not so good.
AKUS Financial Highlights
Over the last trailing twelve months AKUS reported a non-GAAP Earnings per Share(EPS) of -2.62. The EPS decreased by -20.74% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -41.06% | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
AKUS Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 78% to AKUS. The Buy consensus is the average rating of analysts ratings from 11 analysts.